We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Rosetta Genomics Announces First Source for Clinical Validation of its Cancer of Unknown Primary Diagnostic Test

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Rosetta Genomics Announces First Source for Clinical Validation of its Cancer of Unknown Primary Diagnostic Test"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Rosetta Genomics has announced that it has signed an agreement with the Henry Ford Hospital in Detroit, Michigan, to provide the company with samples of metastases found in brain tissue. The samples will then be analyzed using Rosetta Genomics' miRdicator™ technology to determine the origin of the metastasis.

"This is a significant step towards initiating the clinical validation for our cancer of unknown primary diagnostic test, "said Amir Avniel, President and CEO of Rosetta Genomics.

"The samples we will receive from the Henry Ford Hospital will help validate our lead diagnostic program and advance it forward towards launching the first microRNA-based diagnostic test."

The brain is one of the leading sites where metastases of unknown origin are found. Rosetta Genomics CUP (Cancer of Unknown Primary) test is designed to identify the site where the metastasis originated by analyzing the unique microRNA signature of each metastasis and comparing it to the signature of known primary sites.

"Our CUP diagnostic program has been showing rapid progress over the past few months," noted Dalia Cohen, Rosetta Genomics' Global Head of R&D. "We are continually expanding the test, and believe we have reached a point where we can confidently begin running "blind" samples of metastases on our miRdicator™ platform to identify their origin."